Full Recording | Development of New Therapies for Chronic Hepatitis B

Development of New Therapies for Chronic Hepatitis B [Hosted by NIAID]
AGENDA:
- Welcome | John Ward, Director, CGHE
- Introductory Remarks | Jeanne Marrazzo, Director, NIAID, NIH
- HBV replication and natural history | Jianming Hu, Professor, Department of Microbiology and Immunology, Penn State Cancer Institute
- Current treatment | Anna Lok, Assistant Dean for Clinical Research, University of Michigan
New treatments in development:
- Entry inhibitors: Stephan Urban, Head, Translational Virology, German Center for Infection Research (DZIF) - Heidelberg Partner Site, Heidelberg Germany
- Capsid assembly modulators (CAMs): Adam Zlotnick, Distinguished Professor of Molecular and Cellular Biochemistry, Indiana University
- Finding cccDNA inhibitors: Haitao Guo, Professor, Department of Microbiology and Immunology and Co-Leader, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh
- Immunomodulatory strategies | Barbara Rehermann, Chief of the Immunology, Section Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
- Public health perspective (HBV elimination) | Chari Cohen, President, Hepatitis B Foundation
Panel + community representative discussions |
- Anna Lok
- Chari Cohen
- John Ward